DMP-323

DMP–323 is a synthetic small molecule classified as a cyclic urea derivative and functions as an HIV protease inhibitor. It was developed as part of efforts to design potent inhibitors targeting the active site of the HIV–1 protease enzyme—a key enzyme required for viral maturation and replication in human immunodeficiency virus infection. By binding to and inhibiting this protease's activity with high affinity (reported Ki values in the low nanomolar range), DMP–323 blocks cleavage of viral polyproteins into functional proteins necessary for assembly of infectious virions[1][5]. The compound has been studied primarily in preclinical settings.

Other names

(4R,5S,6S,7R)-1,3-dibenzyl-4,7-bis(phenoxymethyl)-5,6-dihydroxy-1,3-diazepan-2-one(4alpha,5alpha,6beta,7beta)-hexahydro-5,6-dihydroxy-1,3-bis((4-(hydroxymethyl)phenyl)methyl)-4,7-bis(phenylmethyl)-2H–1,3–diazepin–2–one(4R-(4A,5A,6B,7B))-HEXAHYDRO–5,6-DIHYDROXY–1.3-BIS((4-(HYDROXYMETHYL)PHENYL)METHYL)–4.7-BIS(PHENYLMETHYL)–2H–1.3-DIAZEPIN–2–ONE